Bioretec Completes Statutory Change Negotiations and Reorganization Plans

Bioretec Concludes Change Negotiations

On December 4, 2025, Bioretec Ltd announced the conclusion of its statutory change negotiations initiated on November 12, 2025, under the Finnish Act on Co-operation within Undertakings. This decision stems from the company's intent to reorganize production and marketing strategies in Finland to bolster its competitiveness and profitability.

The negotiations commenced on November 19 and were a serious examination of Bioretec's internal operations. The company initially projected that up to eight employees could potentially see changes in their employment conditions. Following the completion of the discussions, it was confirmed that two positions would be terminated while five production employees would be temporarily laid off. Additionally, one employee's role will undergo significant modifications.

These changes are expected to yield cost savings of approximately EUR 0.4 million per year, highlighting Bioretec's commitment to maintaining financial health and operational efficiency. A total of 15 employees were part of the negotiation process, reinforcing the company’s transparency regarding its staffing decisions and strategic needs.

In the ongoing analysis of its operational framework, Bioretec is also reassessing its overall commercialization strategy along with its product development pipeline. An official update regarding these aspects is anticipated by the end of 2025, indicating the company's proactive approach in adapting to market challenges and evolving healthcare demands.

About Bioretec

Bioretec is a pioneering global medical device manufacturer headquartered in Finland, specializing in innovative orthopedic solutions utilizing fully biodegradable implant technologies. The firm has gained recognition for its dedication to creating products that interface biologically with active implants, thereby promoting enhanced bone growth and expedited healing of fractures post-surgery.

One of Bioretec's standout product lines is Activa, which features bioabsorbable orthopedic implants composed of a proprietary, self-reinforced PLGA polymer. These implants offer secure fixation and naturally degrade over about two years, alleviating the need for costly surgeries to remove them and fostering optimal bone regeneration. The Activa range is CE marked and FDA cleared, applicable for various uses in both adult and pediatric patients.

Further expanding its innovative scope, Bioretec introduced its latest line, RemeOs™, which uses an advanced magnesium alloy and hybrid composites. This generation of absorbable materials aims to improve surgical outcomes significantly. The RemeOs implants are designed to be absorbed by the body while promoting bone healing, thus removing the necessity for further invasive procedures. The U.S. market authorization for the first RemeOs product was secured in March 2023, followed by CE mark approval in Europe in January 2025.

Bioretec continues to lead in orthopedic treatments, making strides toward providing more effective and patient-centered solutions in healthcare. To learn more about Bioretec and its innovative products, please visit Bioretec's website.